The Research Study

Currently Recruiting

15 Nov 2026

Up to $5,420

Melbourne, Australia

Friedreich’s Ataxia (FA) is a rare, inherited disease that affects the nervous system, muscles, and heart. Symptoms often begin in childhood or adolescence and can progressively impact balance, coordination, walking, speech, and daily activities. Over time, many people with FA experience increasing disability, and serious complications such as heart disease can occur. 

FA is caused by a genetic change that reduces production of a protein called frataxin, which is essential for normal cell function. Because the underlying cause of FA is not fully addressed by current treatment options, there remains a significant need for new therapies that may help restore frataxin levels and potentially slow or modify disease progression. 

We invite you to join our Phase 1 clinical study evaluating an investigative treatment for FA. By participating, you can offer hope to affected families and contribute to a future where FA no longer limits lives. 

Apply now Speak with us 1300 569 066

Join our clinical trial

 This is not a first-in-human (FIH) study, meaning it is not the first time the potential treatment is being tested in people. The investigative therapy has been given to both healthy volunteers and FA patients. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study drug may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur. 

Before joining, you’ll receive detailed information about th e study, meet with a doctor, and have the chance to ask any questions. 

What to expect

  • Participation in a monitored clinical environment 
  • Study visits scheduled  
  • Support from a professional medical team 
  • Reimbursement for your time and commitment 

Study schedule

 

Intake 1 In-clinic stay:

15 November 2026 – 23 November 2026

 Follow-up visits:

25 November 2026
29 November 2026

6 December 2026

Study dates are subject to change. Our team will confirm details with you during the screening process.

Trial details

Study duration

  • 8-night inpatient stay
  • 3 follow-up visits

Study medication

The study drug will be administered in one of two ways: subcutaneous infusion or subcutaneous injection.

Additional eligibility

  • Weigh less than or equal to 100kg at Screening 
  • No significant medical history 
  • Not taking any prescription medication 

Ethics

An independent ethics committee has approved this clinical trial.

Are you a match?

Age

18 - 45 years old

Remuneration

Up to $5,420 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male or Female

BMI

BMI 18 - 32 kg/m2

Commitment

8 nights, 3 clinic visits

Medical condition

Not taking any medications

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg






















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information


Consent to Information Use and Future Contact